
Efficacy Rate80%
Studies3
Participants2,514
StatusAvailable
PT-141
Bremelanotide
PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist specifically designed to treat hypoactive sexual desire disorder in premenopausal women. Unlike other sexual health treatments, PT-141 works through the central nervous system to enhance sexual desire and arousal rather than affecting blood flow or hormones.
Complete Research Database
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.